UPDATE 1-U.S. FDA approves Biomarin's Batten disease drug

April 27 (Reuters) - The U.S. Food and Drug Administration

said on Thursday it had approved Biomarin Pharmaceutical Inc's

drug to treat a type of Batten disease, an extremely

rare disorder that mainly impacts the nervous system.

Read more